BioWorld

Sep. 17, 2003

Celsion Licenses Heat-Activated Gene Therapy Patents From NIH

Rival Game Plans Line Ducks In Row, Hoping For Hopeless Sonic Hedgehog Pancreatic Cancer Cure

Stressgen Drug Hits Endpoint In Prolonging Surgery Interval

Other News To Note

ParAllele, Roche Seek Mutations Associated With Type II Diabetes

ParAllele BioScience Inc., as part of its move to the commercial side of things, signed a deal with Hoffmann-La Roche Inc. to discover genes and genetic variations around Type II diabetes. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...